Navigation

2003/046 NICE recommends rituximab for aggressive non-Hodgkin's lymphoma

The National Institute for Clinical Excellence has issued guidance on the use of rituximab (Mabthera) for the treatment of aggressive non-Hodgkin's lymphoma.

This page was last updated: 29 April 2009

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.